{
  "abstract": "Targeted alpha therapy (TAT) delivers high-linear-energy-transfer radiation over a few cell diameters and is being explored for resistant and microscopic solid-tumor disease. This targeted narrative review evaluates alpha-emitting platforms and clinical evidence by tumor type and development stage, with a focused literature update through 12 October 2026. Unlike broader radiochemistry-centered reviews, we place approved, randomized, early-phase, observational, and preclinical findings in separate evidence tiers. Radium-223 dichloride has randomized survival evidence in symptomatic bone-metastatic castration-resistant prostate cancer, whereas molecularly targeted actinium-225, lead-212, astatine-211, and thorium-227 agents remain investigational in the indications discussed. Updated examples include the 2026 ACTION-1 actinium-225-DOTATATE dosimetry substudy, the 2026 first-in-human astatine-211-MABG study, 2025 lead-212-DOTAMTATE phase II disclosures, and a negative 2025 mesothelin-targeted thorium-227 study. Quantitative outcomes are reported with their study design and limitations rather than interpreted as indirect head-to-head comparisons. Major barriers include isotope supply, incomplete daughter retention, salivary, marrow, and kidney toxicity, spatially heterogeneous target uptake, and uncertainty in patient-specific microdosimetry. We propose practical, imaging-led selection and a priority-ranked translational roadmap.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "Review",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "name": "Qimin Li"
    },
    {
      "name": "Jian Xie"
    },
    {
      "name": "Fei Chen"
    },
    {
      "name": "Laixiang Li"
    },
    {
      "name": "Chuansheng Yang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9jbpxyz51fk7j.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.2007300",
  "fulltext_url": null,
  "id": "9jbpxyz51fk7j",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.2007300",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "feed-journal",
      "medicine/oncology"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-02",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/9jbpxyz51fk7j.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T12:20:48Z",
      "native_id": "10.3389/fonc.2026.2007300",
      "source": "feed-frontiers",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.2007300"
    },
    {
      "first_seen": "2026-11-02T12:24:06Z",
      "native_id": "10.3389/fonc.2026.2007300",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.2007300/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "feed-journal:medicine/oncology",
      "subfield": "oncology"
    }
  ],
  "title": "Targeted alpha therapy for solid tumors: biological rationale, clinical advances, and future perspectives",
  "title_text": "Targeted alpha therapy for solid tumors: biological rationale, clinical advances, and future perspectives",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T00:26:54Z",
  "url": "https://research.draconitic.com/paper/9jbpxyz51fk7j",
  "venue": "Frontiers in Oncology",
  "versions": []
}